VOLUME 18 | NUMBER 3 | MARCH 2012 nature medicine t e c h n i c a l r e p o r t s Aging reduces the number of mesenchymal stem cells (MSCs) that can differentiate into osteoblasts in the bone marrow, which leads to impairment of osteogenesis. However, if MSCs could be directed toward osteogenic differentiation, they could be a viable therapeutic option for bone regeneration. We have developed a method to direct MSCs to the bone surface by attaching a synthetic high-affinity and specific peptidomimetic ligand (LLP2A) against integrin a4b1 on the MSC surface to a bisphosphonate (alendronate, Ale) that has a high affinity for bone. LLP2A-Ale induced MSC migration and osteogenic differentiation in vitro. A single intravenous injection of LLP2A-Ale increased trabecular bone formation and bone mass in both xenotransplantation studies and in immunocompetent mice. Additionally, LLP2A-Ale prevented trabecular bone loss after peak bone acquisition was achieved or as a result of estrogen deficiency. These results provide proof of principle that LLP2A-Ale can direct MSCs to the bone to form new bone and increase bone strength.
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A decrease in the number of MSCs in the bone marrow with aging leads to reduced osteogenesis and bone formation [1] [2] [3] . Bone regeneration through induction of MSCs could promote osteogenesis and provide a rational therapeutic strategy for preventing age-related osteoporosis. Both autologous and allogeneic stem cells have been successfully infused for the treatment of degenerative heart or neuronal diseases or for injury repair [4] [5] [6] . However, systemic infusions of MSCs in vivo do not promote an osteogenic response in bone because of the inability of MSCs to home to the bone surface unless they have been genetically modified [7] [8] [9] [10] or are infused after certain conditions, such as injuries 8, 11, 12 . This issue has become a major obstacle for MSC transplantation 13, 14 . Even if the transplanted MSCs make it to the bone, they are usually observed engrafted in the upper metaphysis or the epiphysis or are within the bone marrow sinusoids or the Haversian system [14] [15] [16] , rather than at the bone surface. Subsequently, the cells are removed from bone marrow within 4-8 weeks after infusion and do not show long-term engraftment 14, 15, 17 .
MSCs within bone marrow have a multi-lineage potential and give rise to the following cell types: osteoblasts, chondrocytes and adipocytes 18, 19 . MSCs undergo osteogenic differentiation in the bone marrow 9, 20 , and mobilization of the osteoblastic progenitors to the bone surface is a crucial step in osteoblast maturation and the formation of mineralized tissue 21, 22 . Bone cells at all maturation stages are dependent on cell-matrix and cell-cell interactions 23, 24 . Once the osteoblastic progenitors are directed to the bone surface, they synthesize a range of proteins, including osteocalcin, osteopontin, bone sialoprotein, osteonectin, type-I collagen and fibronectin, that will further enhance the adhesion and maturation of the osteoblasts 25, 26 . These interactions are mostly mediated by transmembrane integrin receptors that primarily utilize an arginine, glycine, aspartate (ArgGlyAsp) sequence to identify and bind to specific ligands. MSCs express integrins α1, α2, α3, α4, α5, α6, α11 and β1 (ref. 27) , whereas integrins with a β1 subunit are reported to be expressed in the osteoblasts 23, 25 . Integrin α5 is required for MSC osteogenic differentiation 28 , and overexpression of integrin α4 in MSCs has been reported to increase the homing of MSCs to bone 29 . These studies suggest that a therapeutic strategy for bone regeneration could be directed toward the integrins on the surface of the MSCs and could bring the MSCs to the bone surface.
We used a one-bead-one-compound combinatorial library method to develop a high-affinity and specific peptidomimetic ligand, LLP2A, against activated α4β1 integrin (half maximal inhibitory concentration (IC 50 ) = 2 pM) 30 . However, scrambled LLP2A ligand loses its affinity to α4β1 (ref. 30) . We conjugated LLP2A to a bisphosphonate, alendronate, which served as a bone-seeking component, to direct both the cells and the compound to bone. We hypothesized this hybrid compound, LLP2A-Ale ( Supplementary Fig. 1) , could be used to direct MSCs to bone and augment bone formation.
RESULTS

General in vivo and in vitro effects
We treated mice with a wide range of doses of LLP2A-Ale (0.03-2 nmol) and did not observe organ toxicity at any of the doses, as evaluated by standard measurements of weight, kidney and liver function and calcium metabolism. In addition, we did not observe extraskeletal calcifications in mice treated with either LLP2A or LLP2A-Ale.
We used color-coded peptide beads (rainbow beads) to semiquantitatively determine the integrin profiles of MSCs undergoing osteogenic differentiation 31 . We found that the α4β1 integrin was highly expressed in the osteoprogenitor cells and had a high affinity for LLP2A ( Supplementary Fig. 2 ). Treatment with LLP2A-Ale increased both the number of MSCs that differentiated into osteoblasts ( Fig. 1a-c) as well as the migration of the MSCs (Fig. 1d,e ), but did not affect their chondrogenic or adipogenic potentials.
LLP2A-Ale increases the bone homing and retention of MSCs
To determine whether LLP2A-Ale could direct transplanted MSCs to bone, we performed a xenotransplantation study. We intravenously (i.v.) injected human MSCs (huMSCs) or huMSCs plus LLP2A-Ale into nonobese diabetic (NOD)/severe combined immunodeficiency (SCID)/mucopolysaccharidosis type VII (MPS VII) mice. Twentyfour hours after the i.v. injections, we observed a number of huMSCs adjacent to the periosteal, endocortical and trabecular bone surfaces in the lumbar vertebral bodies (LVB) of the mice co-injected with LLP2A-Ale and huMSCs but not of the mice injected with huMSCs only ( Fig. 2a) .
At 3 weeks after injection, we observed huMSC cells adjacent to the bone surface and embedded within the bone matrix in the mice treated with huMSC and LLP2A-Ale but not in those treated with huMSCs only, suggesting that there was retention of the transplanted huMSCs ( Supplementary Fig. 3a ) in the bone of the former group. We observed higher concentrations of procollagen type I aminoterminal prepeptide (P1NP), an early osteoblast differentiation marker, in the mice treated with LLP2A-Ale + huMSCs compared to npg mice treated with huMSCs only. The concentrations of osteocalcin, an osteoblast maturation marker, and the bone formation parameters were higher in mice treated with LLP2A-Ale and those treated with huMSCs + LLP2A-Ale compared to the mice treated with PBS or huMSCs only (Fig. 2b) .
In mice that we treated with GFP-labeled mouse MSCs or with LLP2A-Ale, the mice given the GFP-labeled mouse MSCs + LLP2A-Ale combination treatment showed higher numbers of the GFP-positive osteoblasts and osteocytes in both their trabecular ( Fig. 2c ) and cortical bone regions ( Supplementary Fig. 3b 
LLP2A-Ale augments bone formation in immunocompetent mice
To determine whether LLP2A-Ale could augment endogenous bone formation in immunocompetent mice without MSC transplantation, we used 2-month-old female 129/SvJ mice that received two doses of LLP2A-Ale, representing the effective dose compared to the placebo, LLP2A or Ale treatments and the maximum anabolic dose in our dosefinding studies. Two days after the i.v. injections, the cell populations expressing LLP2A, runt related transcription factor 2 (Runx2) (a gene marker for osteoblast maturation) and bromodeoxyuridine (Brdu) (a thymidine analog that is used in the detection of cell proliferation) were primarily located within the bone marrow in the LLP2A-treated mice but were located at the bone surface in the mice treated with LLP2A-Ale (Supplementary Fig. 4) . The LLP2A and Brdu-positive cell populations were not detectable in the LVB at 21 d after injection in mice either injected with LLP2A or LLP2A-Ale. Treatment with both doses of LLP2A-Ale induced a higher distal femoral trabecular bone volume (measured as trabecular bone volume (BV)/tissue volume (TV)) and thickness compared to baseline (Fig. 3a-c) , with a corresponding greater maximum load and strength of the LVB in mice treated with LLP2A-Ale compared to mice treated with PBS, aledronate or LLP2A alone at 12 weeks after treatment ( Fig. 3d) . At 12 weeks after treatment, LLP2A-Ale dose-dependently resulted in a higher concentration of osteocalcin ( Fig. 3e ) and the surface-based bone-formation parameters at the distal femur in the LLP2A-Ale treated mice as compared to the groups treated with PBS or Ale only (Fig. 3f) . More notably, LLP2A-Ale treatment increased the parameter of the osteoblast surface and formed bridges between adjacent trabeculae (Fig. 3g) . Bone-formation rates on the endocortical surfaces of the tibial shafts were higher in mice that received LLP2A or LLP2A-Ale as compared to mice that received PBS or Ale (Fig. 3h,i) .
LLP2A-Ale prevents trabecular bone loss in osteopenia mice
C57BL/6 mice usually achieve their peak bone mass by 6-8 weeks of age, and this peak is followed by an approximately 50% decline in both bone formation and bone mass at between 2 and 4 months of age 32, 33 . Treatment with LLP2A-Ale in C57BL/6 mice prevented age-related trabecular bone loss after peak bone acquisition was achieved (Fig. 4a) , with higher amounts of bone-formation parameters being present at the distal femur (Fig. 4b,c) as well as at the LVB in these mice compared to mice treated with PBS ( Fig. 4d,e) . We observed osteoblast bridges at both of these trabecular bone sites (Fig. 4e) in LLP2A-Ale-treated mice. These data suggest that one i.v. injection of LLP2A-Ale prevented age-related reductions in trabecular bone mass and bone formation for up to 8 weeks after injection in C57BL/6 mice.
To determine whether LLP2A-Ale could prevent bone loss in a disease state, we treated 10-week-old ovariectomized (OVX) mice with PBS, Ale, LLP2A, LLP2A-Ale or parathyroid hormone (PTH) 2 weeks after OVX (Fig. 5a) . LLP2A-Ale treatment induced a larger osteoblast surface and a larger mineralizing surface, as well a higher bone-formation rate per total bone surface at the LVB in npg t e c h n i c a l r e p o r t s treated mice compared to the groups treated with PBS, Ale or LLP2A ( Fig. 5b-d) . Mice treated with either LLP2A-Ale or PTH had more endocortical bone formation compared to the mice treated with PBS or Ale (Fig. 5e,f) . Cortical bone thickness and maximum stress were not significantly altered by OVX or by treatment with Ale, LLP2A, one single i.v. injection of LLP2A-Ale or 4 weeks of PTH (Fig. 5e) . These data suggest an activation of endosteal bone formation by LLP2A-Ale that is comparable to that by PTH in this acute estrogen deficiency model.
DISCUSSION
MSCs are precursors of osteoblasts. MSCs do not readily migrate to the bone, and this creates a major obstacle for the use of MSCs for bone regeneration. We have developed a ligand that targets integrin α4β1, a protein that is highly expressed by MSCs undergoing osteoblast differentiation. Instead of using genetically modified MSCs, we attached LLP2A to a bisphosphonate (Ale) to guide the MSCs to the bone surface. Bisphosphonates are prescribed to reduce bone resorption and improve bone strength. Because we used approximately one-tenth of the therapeutic dose of Ale in our compound, we did not observe any anti-resorptive effects as a result of treatment. We observed an uncoupling of bone remodeling with bone formation and no marked changes in bone resorption during this short-term study period. This uncoupling of bone remodeling in favor of bone formation is also observed in short-term treatment with the anabolic agent human PTH (hPTH) (1-34) 34 . We hypothesized that we would also see a return to a coupling of bone turnover with this intervention after a longer treatment period. Additionally, the Ale concentrations that we used in these studies did not suppress TGF-β1 secretion (Supplementary Fig. 5 ), a growth factor that is crucial for coupling bone resorption and endogenous stem-cell recruitment to bone 35 . In our xenotransplantation model, LLP2A-Ale increased homing and retention of the transplanted MSCs to bone, which indicates a breakthrough in using transplanted MSCs to augment bone formation. We found the transplanted human or mouse MSCs embedded in the bone matrix as osteocytes or adjacent to the bone surface as osteoblasts. In addition to increasing bone formation rates at both the endocortical and trabecular surfaces, the periosteal bone formation rate also increased after MSC transplantation and after treatment with LLP2A-Ale. This is notable, as the total cross-sectional area increase as a result of periosteal expansion is the most important determinant of npg bone strength 36 . Our finding that LLP2A-Ale can direct transplanted human MSCs to the bone is of major importance. This approach provides a means to overcome a major obstacle of using MSCs in the treatment of bone degenerative diseases and, as such, may be a new treatment option for osteoporosis.
Further, LLP2A-Ale might also increase endogenous MSC osteoblast differentiation and augment bone formation. We could not directly track the endogenous MSCs lineage commitment to osteoblasts, as there is no single marker that would allow us to define or track the migration of the endogenous MSCs to bone or their osteoblast differentiation in vivo. However, we were able to partially overcome this limitation by using control groups that we administered equivalent doses of Ale and LLP2A. Because LLP2A is a specific ligand for activated α4β1 integrin, our findings support the previous report that targeting α4 alone could increase the homing of MSCs to bone 37 . However, LLP2A by itself did not induce any marked changes in the bone architectures. In contrast, LLP2A-Ale enhanced osteoblast activities, as evidenced by the increased osteocalcin concentrations and increased bone formation in response to treatment that were primarily seen at the trabecular and endocortical bone surfaces that are in close contact with the bone marrow. Treatment with LLP2A-Ale not only increased the vertebral maximum load but also increased maximum bone stress, a parameter that is independent of bone shape, suggesting LLP2A-Ale treatment increased bone quality in addition to the observed increase in bone mass. Similarly, treatment with LLP2A-Ale prevented trabecular bone loss after peak bone mass had been achieved in C57BL/6 mice and partially prevented the rapid trabecular bone loss that is induced by OVX in these mice. Collectively, our findings show that LLP2A-Ale might be able to increase the migration of endogenous MSCs to bone, stimulate osteoblastic differentiation, augment bone formation and increase bone mass in young mice, as well as prevent trabecular bone losses associated with aging or estrogen deficiency. These results differ from what we observed in NOD/SCID/MPS VII mice that we treated with huMSCs and LLP2A-Ale, in which the combination treatment increased periosteal bone formation. This may have been a result of the lack of periosteal effects by LLP2A-Ale itself, the combination treatment may require more than one injection or a longer treatment period to achieve cortical bone responses.
In summary, we have shown that LLP2A-Ale augments endogenous bone formation and directs the transplanted MSCs to the bone to augment bone formation and bone mass. This new approach to increase the homing and retention of the MSCs to bone should now be examined in both preclinical and clinical studies for the treatment of osteoporosis and fracture repair.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
